Title Page
Contents
ABSTRACT 8
Ⅰ. INTRODUCTION 10
1.1. Clinical Significance of Early Treatment for Non-Alcoholic Fatty Liver Disease (NAFLD) 10
1.2. Limitations in Early Detection of NAFLD and Their Alternative Serological Parameters 10
1.3. Mechanistic, and Clinical Evidence for Fibrates as Therapeutic Candidates for NAFLD 12
Ⅱ. AIM OF THE STUDY 14
Ⅲ. MATERIALS AND METHODS 15
3.1. Data Source 15
3.2. Study Population, and Design 15
3.3. Outcome Measurements and Statistical Analysis 16
Ⅳ. RESULTS 19
4.1. Population Characteristics 19
4.2. The Effect of Fibrates on the Progression of Fatty Liver 19
4.3. The Effect of Fibrates on Changes in FLI and HSI and Their Components 20
Ⅴ. DISCUSSION 22
5.1. Strengths of the Study 22
5.2. Limitation of the Study 23
Ⅵ. CONCLUSION 26
REFERENCES 39
ABSTRACT (IN KOREAN) 42
Table 1. Baseline characteristics of the study population before and after propensity-score matching 28
Table 2. Comparison of effects on reduction of hepatic steatosis estimated by fatty liver index (FLI) and hepatic steatosis index (HSI) in fibrate treatment group and control group 32
Table 3. The effect of fibrates on fatty liver index (FLI) and hepatic steatosis index (HSI) and their components according to medication possession ratio (MPR) 34
Figure 1. Stud Flow 27